• CSL and AstraZeneca have agreed for CSL to manufacture approximately 50 million doses of Vaccine AstraZeneca in Australia for supply to the country. First doses were rolled out in March 2021.
• CSL Behring has launched a clinical trial into the use of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia. A Phase 2 study to assess the safety and efficacy of the potential treatment has completed enrollment and results are expected in the second quarter of 2021.
• Seqirus has donated its well-established adjuvant technology – MF59® – to the vaccine efforts of multiple entities, including the University of Queensland vaccine development program. MF59® is used in the company’s adjuvanted seasonal flu vaccine for the over-65 age group -- one of the most vulnerable populations to COVID-19. Adjuvants can help improve immune response and reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly. In parallel, Seqirus remains focused on the production of seasonal influenza vaccines, the importance of which is very much underscored by the COVID-19 pandemic.
• CSL Behring is partnering with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, to advance and deliver a novel immunotherapy targeting COVID-19. The potential therapy would be produced without the need for blood plasma donations from recovered COVID-19 patients. A Phase 1 clinical trial is ongoing.
• CSL is evaluating additional assets in its portfolio and partnerships with external researchers for potential use in the fight against COVID-19.
• CSL Behring co-founded the CoVIg-19 Plasma Alliance, an unprecedented industry of 11 plasma companies across 13+ countries and five continents, to develop a potential plasma-derived hyperimmune therapy for treating COVID-19. The one-year collaboration concluded in April 2021 after a Phase 3 clinical trial of the potential therapy did not meet its endpoints. More information is available here. In addition, CSL’s work on an Australian hyperimmune, which was dependent on positive data, has also been discontinued.
• In 2020, CSL worked with the University of Queensland in the early stages of its UQ-CSL v451 COVID-19 vaccine candidate. A Phase 1 clinical trial showed that the vaccine elicited a robust response towards the virus and has a strong safety profile. However, following consultation with the Australian Government, CSL did not progress the vaccine candidate to Phase 2/3 clinical trials. More information is available here.
• Additionally, from the time the coronavirus was first identified in Wuhan, China – where CSL Behring has a manufacturing facility – the company has been assisting in the fight against COVID-19 in a number of ways including offering expertise, technologies, equipment and materials on a humanitarian basis.

For the latest information from CSL Behring around its work in the fight against COVID-19, please visit: www.csl.com

About CSL
 CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent seasonal and pandemic influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 100 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients and communities can live life to the fullest. For more information about CSL Limited, visit www.csl.com